Recker R R, Bare S P, Smith S Y, Varela A, Miller M A, Morris S A, Fox J
Osteoporosis Research Center, Creighton University, Omaha, NE 68131, USA.
Bone. 2009 Jan;44(1):113-9. doi: 10.1016/j.bone.2008.09.019. Epub 2008 Oct 17.
Treatment with parathyroid hormone [PTH(1-84)] increases lumbar spine bone mineral density and decreases vertebral fractures, but its effects on bone microarchitecture are unknown. We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure. At 18 months, cancellous bone volume (BV/TV) measured by microcomputed tomography and histomorphometry was 45-48% higher in subjects treated with PTH(1-84) versus placebo, a result of higher trabecular number (Tb.N) and thickness. The higher Tb.N appeared to result from intratrabecular tunneling. Connectivity density was higher and structure model index was lower, indicating a better connected and more plate-like trabecular architecture. Cancellous bone formation rate (BFR) was 2-fold higher in PTH(1-84)-treated subjects, primarily because of greater mineralizing surface. Osteoblast and osteoid surfaces were a nonsignificant 58% and 35%, respectively, higher with PTH(1-84) treatment. Osteoclast and eroded surface were unaffected by PTH(1-84). There were no effects of PTH(1-84) treatment on cortical thickness, or endocortical or periosteal BFR, but cortical porosity tended to be higher. Although cancellous BFR was lower at 24 than at 18 months, measures of cancellous and cortical bone structure were similar at both timepoints. The bone produced by PTH(1-84) had normal lamellar structure and mineralization with no abnormal histology. In conclusion, when compared with placebo, treatment of osteoporotic women with PTH(1-84) was associated with higher BV/TV and trabecular connectivity, with a more plate-like architecture, all consistent with the lower vertebral fracture incidence.
甲状旁腺激素[PTH(1 - 84)]治疗可增加腰椎骨矿物质密度并减少椎体骨折,但其对骨微结构的影响尚不清楚。我们对接受安慰剂治疗(n = 8)或100微克PTH(1 - 84)治疗18个月(n = 8)或24个月(n = 7)的绝经后骨质疏松女性进行了髂嵴活检,以评估松质骨和皮质骨的形成及结构。18个月时,通过微计算机断层扫描和组织形态计量学测量,接受PTH(1 - 84)治疗的受试者的松质骨体积(BV/TV)比接受安慰剂治疗的受试者高45% - 48%,这是小梁数量(Tb.N)和厚度增加的结果。较高的Tb.N似乎是由小梁内隧道形成导致的。连接密度更高且结构模型指数更低,表明小梁结构连接更好且更呈板层状。接受PTH(1 - 84)治疗的受试者的松质骨形成率(BFR)高出2倍,主要是因为矿化表面更大。成骨细胞和类骨质表面分别仅高出58%和35%,差异无统计学意义。破骨细胞和侵蚀表面不受PTH(1 - 84)影响。PTH(1 - 84)治疗对皮质厚度、内皮质或骨膜BFR无影响,但皮质孔隙率有升高趋势。尽管24个月时的松质骨BFR低于18个月时,但两个时间点的松质骨和皮质骨结构测量结果相似。PTH(1 - 84)产生的骨具有正常的板层结构和矿化,无异常组织学表现。总之,与安慰剂相比,用PTH(1 - 84)治疗骨质疏松女性与更高的BV/TV和小梁连接性相关,且具有更呈板层状的结构,所有这些都与较低的椎体骨折发生率一致。